Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled

Inclusion criteria: * Patients with type 2 diabetes mellitus inadequately controlled despite a treatment with sulfonylurea (SU) alone or metformin alone or a free combination of SU and metformin prior to the study entry. * Signed informed consent, obtained prior any study procedure Exclusion criteria: * Age \< legal age of adulthood * HbA1c \< 7% or ≥ 11% * BMI \> 35 kg/m2 * Treatment with a stable dose of maximally tolerated SU alone or metformin alone or the free combination of SU and metformin for less than 12 weeks prior to the screening visit. * Patients who received any anti-diabetic drug other than SU or metformin within 12 weeks prior to the screening visit. * Diabetes other than type 2 diabetes (e.g. type 1 diabetes, diabetes secondary to pancreatic disorders, drug or chemical agent intake…) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.